Integrated safety analysis of filgotinib in Japanese patients with moderately to severely active rheumatoid arthritis over a treatment duration of up to 5 years.
Mod RheumatolAug 31, 2026
Clinical ResearchRheumatology
Yoshiya Tanaka, Akira Kondo, Hisaaki Isaji et al.
✦ AI-curated · Sources linked
In 30 seconds
This multicenter Phase III clinical trial evaluated the long-term safety of filgotinib in Japanese patients with moderately to severely active rheumatoid arthritis over a treatment duration of up to 5 years. The study found that 97% of patients experienced treatment-emergent adverse events, with an event incidence rate (EAIR) of 29.1 per 100 patient-years.
Key findings
- 97% of patients experienced treatment-emergent adverse events.
- EAIR for serious infections was 2.7 for FIL200 and 2.0 for FIL100.
- EAIR for herpes zoster was 3.1 for FIL200 and 2.6 for FIL100.
- There were 0 and 2 incidents of all-cause mortality in the FIL200 and FIL100 groups, respectively.
Why it matters
Understanding the long-term safety profile of filgotinib is crucial for clinicians managing rheumatoid arthritis, as it informs treatment decisions and patient counseling regarding potential adverse effects.